Resoundant, Inc. articles

Abstract

Background and aim:

Nonalcoholic fatty liver disease (NAFLD) patients with significant hepatic fibrosis (stage ≥ 2) are at increased risk of liver-related morbidity and are candidates for pharmacologic therapies. In this study, we compared the diagnostic accuracy of MEFIB (the combination of magnetic resonance elastography [MRE] and FIB-4) and FAST (FibroScan-AST; combined liver stiffness measurement by vibratio

Abstract

Almost all patients achieved sustained virological response (SVR) by direct-acting antivirals (DAA) therapy, but it is not clear as to what extent DAA therapy affects changes in liver fibrosis after achieving SVR. In this study, we investigated the changes of liver stiffness by magnetic resonance elastogaraphy (MRE) during DAA therapy. A total of 308 patients were enrolled in the study. Liver stiffness was measured twice before and after DA

A new study was published in March of 2021 demonstrating that elevated liver stiffness, as measured by magnetic resonance elastography (MRE), is associated with higher rates of cardiovascular disease in patients with non-alcoholic fatty liver disease (NAFLD). As clinical researchers, regulators and pharmaceutical partners pursue noninvasive biomarkers